NR1H4 and metabolic dysfunction-associated steatotic liver disease: Moreover, activation of FXR results in hepatoprotection in mouse models of Non Alcoholic Fatty Liver Disease (NAFLD) possibly mediated via a reduction of lipid accumulation, fibrosis and inflammation [12]–[14].